FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1348-1349 November 17, 1994 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

In 1972, topical tretinoin (Retin-A, Ortho Pharmaceutical) was approved for the treatment of acne. Today this remains the only medical indication for its use approved by the Food and Drug Administration (FDA). In 1988 a highly publicized study reported that topical tretinoin improves the appearance of "photoaged" skin¹. Since then, the manufacturer of topical tretinoin has conducted an active, controversial multimedia effort to ensure that the general public and the medical profession are aware of the "unlabeled" use of tretinoin to treat benign cutaneous changes, such as wrinkles and brown spots, that may be annoying to patients because of . . . [Full Text of this Article]

Methods

Results

Discussion

Source Information

From the Department of Dermatology, Beth Israel Hospital, and Harvard Medical School, Boston.

Address reprint requests to Dr. Stern at Beth Israel Hospital, 330 Brookline Ave., Boston, MA 02215.

References

Related Letters:

Drug Promotion
Hoberman D., Puma J. L., Cohen S. N., Mossinghoff G. J., Stryer D. B., Bero L. A., Kalish R. S., Kessler D. A., Rose J. L., Temple R. J., Schapiro R., Griffin J. P., Stern R. S.
Extract | Full Text  
N Engl J Med 1995; 332:1031-1033, Apr 13, 1995. Correspondence

This article has been cited by other articles:

• Hoberman, D., Puma, J. L., Cohen, S. N., Mossinghoff, G. J., Stryer, D. B., Bero, L. A., Kalish, R. S., Kessler, D. A., Rose, J. L., Temple, R. J., Schapiro, R., Griffin, J. P., Stern, R. S. (1995). Drug Promotion. NEJM 332: 1031-1033 [Full Text]